LPXN抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09902(LPXN Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09902(LPXN Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

Leupaxin (LPXN) is a cytosolic adaptor protein primarily expressed in hematopoietic cells, including macrophages, osteoclasts, and platelets. It belongs to the paxillin family of proteins, which mediate signal transduction by coordinating protein interactions at focal adhesions and cytoskeletal sites. LPXN contains four leucine-rich LD motifs and four LIM domains, enabling interactions with structural and signaling molecules such as FAK, Pyk2. and integrins. These interactions facilitate its role in regulating cell adhesion, migration, and survival through integrin-mediated signaling pathways.

Initially identified for its homology to paxillin, LPXN exhibits tissue-specific expression patterns, with prominent roles in immune and bone-resorbing cells. Studies highlight its involvement in osteoclast differentiation, platelet activation, and immune cell recruitment. Dysregulation of LPXN has been linked to pathological conditions, including cancer metastasis (e.g., prostate and breast cancers), autoimmune diseases, and thrombosis. For example, elevated LPXN expression in leukemia cells correlates with chemoresistance, while its suppression in osteoclasts impairs bone remodeling.

LPXN antibodies are critical tools for detecting protein expression, localization, and interaction partners in both research and diagnostics. They help elucidate LPXN’s mechanistic contributions to cellular processes and disease progression, offering potential therapeutic targets. Commercial LPXN antibodies are typically validated for applications like Western blotting, immunohistochemistry, and immunoprecipitation. Ongoing research focuses on its role in tumor microenvironment modulation and hematopoietic disorders, reinforcing its relevance in translational medicine.